EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

I Vergote; LM Randall; E Kalbacher; K Madsen; E Van Nieuwenhuysen; A González-Martín; D Cibula; B Monk; L Woelber; S Banerjee; A Westermann; N Colombo; D Lorusso; P Calvert; RL Coleman; C Marth; I Soumaoro; S Jain; B Slomovitz

doi:10.1136/ijgc-2021-IGCS.326

Article info

E-Posters

E-Poster Viewing

EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

Free

Authors

I Vergote Leuven Cancer Institute, Bgog and University Hospitals Leuven, Leuven, Belgium PubMed articles Google scholar articles
LM Randall Massey Cancer Center, Virginia Commonwealth University, Department of Obstetrics and Gynecology, Richmond, USA PubMed articles Google scholar articles
E Kalbacher Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens and CHRU Jean Minjoz, Oncology, Besançon, France PubMed articles Google scholar articles
K Madsen Rigshospitalet, University Hospital of Copenhagen, and Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Centre For Cancer and Organ Diseases, Copenhagen, Denmark PubMed articles Google scholar articles
E Van Nieuwenhuysen Leuven Cancer Institute, Bgog and University Hospitals Leuven, Leuven, Belgium PubMed articles Google scholar articles
A González-Martín Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Clínica Universidad de Navarra, Department of Medical Oncology, Madrid, Spain PubMed articles Google scholar articles
D Cibula Central and Eastern European Gynecologic Oncology Group (CEEGOG), General University Hospital, Charles University, Department of Obstetrics and Gynecology and First Faculty of Medicine, Prague, Czech Republic PubMed articles Google scholar articles
B Monk Arizona Oncology (US Oncology Network), Gynecologic Oncology, Obstetrics and Gynecology, Phoenix, USA PubMed articles Google scholar articles
L Woelber AGO and University Medical Center Hamburg-Eppendorf, Department of Gynecology, Hamburg, Germany PubMed articles Google scholar articles
S Banerjee The National Cancer Research Institute and The Royal Marsden NHS Foundation Trust, Gynaecology Unit, London, UK PubMed articles Google scholar articles
A Westermann Amsterdam University Medical Centers, Department of Medical Oncology, Amsterdam, Netherlands PubMed articles Google scholar articles
N Colombo University of Milan-Bicocca, European Institute of Oncology, IRCCS and Mario Negri Gynecologic Oncology Group, Gynecologic Oncology Program, Milan, Italy PubMed articles Google scholar articles
D Lorusso Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies Group (MITO) and Scientific Directorate and Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Gynaecology Oncology Unit, Rome, Italy PubMed articles Google scholar articles
P Calvert Cancer Trials Ireland, Gynaecology, Dublin, Ireland PubMed articles Google scholar articles
RL Coleman US Oncology Research, Department of Gynecologic Oncology, The Woodlands, USA PubMed articles Google scholar articles
C Marth Arbeitsgemeinschaft Gynäkologische Onkologie Austria (AGO-Austria), Medizinische Universität Innsbruck, Department of Obstetrics and Gynecology, Innsbruck, Austria PubMed articles Google scholar articles
I Soumaoro Genmab US, Inc., Oncology, Plainsboro, USA PubMed articles Google scholar articles
S Jain Seagen Inc., Late Stage Development, Bothell, USA PubMed articles Google scholar articles
B Slomovitz Broward Health, Department of Gynecologic Oncology, Fort Lauderdale, USA PubMed articles Google scholar articles

Citation

Vergote I, Randall L, Kalbacher E, et al

EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)

International Journal of Gynecologic Cancer 2021;31:A129-A130.

Publication history

First published November 1, 2021.

Online issue publication

November 01, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password